501. Risk Factors for Persistent Active COVID-19 Among Patients Receiving B-Cell Depleting Therapy versus Non-B-Cell Immunosuppression

BACKGROUND: Cases of COVID-19 characterized by prolonged replication of SARS-CoV-2 (persistent active COVID [PAC]) have been reported among immunocompromised patients, particularly those receiving B-cell depleting therapy (BCDT); however, the risk has not been quantified. We aimed to identify risk f...

Descripción completa

Detalles Bibliográficos
Autores principales: Voll, Kevin, Kartes, Jacob, Spivak, Emily S, Imlay, Hannah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677509/
http://dx.doi.org/10.1093/ofid/ofad500.570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677509/
http://dx.doi.org/10.1093/ofid/ofad500.570

Ejemplares similares